echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Introducing the Innovative Diagnosis Technology of early screening of tumor, digital biology has reached strategic cooperation with MDNA company in the United States

    Introducing the Innovative Diagnosis Technology of early screening of tumor, digital biology has reached strategic cooperation with MDNA company in the United States

    • Last Update: 2019-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    September 9, 2019 / AP / -- Zhejiang Shuwen Biotechnology Co., Ltd and MDNA Life Sciences Inc of the United States jointly announced that they have signed a formal agreement on the cooperative development and promotion of MDNA's liquid biopsy biomarkers for tumors and other diseases in Greater China According to the agreement, SDB has the exclusive right to develop and promote MDNA's prostate cancer liquid biopsy markers (mpttm) in Greater China (mainland China, Taiwan, Hong Kong, Macao) In addition, the two sides will further cooperate in the development and commercialization of liquid biopsy markers in other diseases With the aging of the population, the number of prostate cancer patients is growing rapidly in China, and the traditional PSA detection accuracy is poor, which is difficult to meet the physical examination and clinical needs MDNA's mpttm technology is based on simple gene amplification for prostate cancer detection and screening of blood samples, with high accuracy and specificity MDNA has reached a promotion on this technology and product in 25 other countries Cooperation Chris, CEO of MDNA Mr Milton said: "we are very honored to cooperate with digital biology The team of digital biology has rich experience in the development and promotion of molecular diagnostic markers We believe that with the development and promotion of digital biology in Greater China based on our MPT and other innovative technologies, it can bring revolutionary improvements to the screening and diagnosis of prostate cancer and other diseases in this region." Dr Zhang Yizhe, founder and CEO of digital biology, said: "innovative diagnostic markers can bring new health possibilities to patients We are glad to reach strategic cooperation with MDNA company to develop new disease screening and diagnostic products based on liquid biopsy for China, to meet clinical needs, especially early screening and early diagnosis of tumors, to save medical costs for the country and improve greatly People's health level " MDNA Life Sciences Inc is a leading innovative diagnostic product R & D company located in the United States and the United Kingdom Based on its unique technology platform, MDNA Life Sciences Inc is carrying out the discovery of diagnostic markers and the development of liquid biopsy diagnostic products The pre-developed prostate cancer diagnostic kit products have been certified by the European Union and have been promoted in 25 countries Digital biology is a leading diagnosis company with the enterprise strategy of "innovation, patent and international cooperation" It is committed to the construction of a unique medical diagnosis innovation and transformation platform in the industry Through international cooperation, combined with independent innovation, it has obtained more than 100 exclusive diagnosis patents, successfully developed a number of new diagnosis products and services initiated by the same kind, and has formed a diagnosis company covering maternal and infant medicine, cancer , serious and public health prevention and screening products Digital biology also provides the development of companion diagnostic reagents and clinical test sample testing services, and provides one-stop services on companion diagnosis for new drug research and development companies The company has nearly 10000 square meters of R & D and testing laboratories, diagnostic kits production and quality inspection facilities, and has passed ISO13485 quality management system certification and other professional certifications Its digital observation medical testing center is a third-party independent laboratory certified by the American Association of Pathologists (CAP), which can provide high-quality medical testing services Digital biology will continue to innovate and launch exclusive diagnostic products to open up new health possibilities for human beings Source: digitarians
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.